{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:33:40Z","timestamp":1793291620359,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":304,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Focal irreversible electroporation (IRE) is an attractive choice for patients aiming to obtain local control of prostate cancer, while decreasing the postoperative risk of impotence and incontinence compared to whole-gland treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective review of a single centre prospective database of 171 consecutive primary IRE procedures for localised prostate cancer. Primary outcomes include oncological infield and out-of-field progression. Secondary objectives include post-IRE continence and impotence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The median follow-up is 35 months (3\u201390 months). The median diameter of the treated lesions is 11\u2009mm (4\u201324\u2009mm). Most patients had PI-RADS 4\u20135 abnormalities on prostate MRI, and 25 patients (15%) had ISUP grade 4\u20135 cancer. Of the 135 patients with &gt;12 months follow-up, 84 had a surveillance biopsy of whom 8.3% had significant infield persistence, with significant out-of-field cancer in 14.3%. There was no difference in the risk of infield cancer persistence regardless of the pre-IRE ISUP score (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.8), or tumour location (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.9). The presence of low volume out-of-field cancer at diagnosis did not increase the risk of post-IRE cancer persistence\/progression (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.7). The prostate PSMA PET SUVmax of \u226510 did not increase the risk of infield or out-of-field recurrence of cancer (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.3). A PSAD\u2009&gt;\u20090.15 did not increase the risk of infield persistence or out-of-field progression of cancer (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.8). Urinary continence was maintained in 167\/171 (97.6%), while erectile function was maintained in 94\/112 (84%) of sexually active patients who completed questionnaires.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Of the patients who proceeded to post-IRE biopsy, 92% had infield ablation of clinically significant cancer with a low risk of urinary incontinence or impotence. Focal IRE of prostate cancer has promising short to medium-term outcomes and is associated with low risks of impotence and incontinence. Long-term follow-up of out-of-field progression risk is required.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41391-026-01148-x","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:42:36Z","timestamp":1788244956000},"page":"1036-1041","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oncological and functional outcomes of focal irreversible electroporation for localised prostate cancer: a single institution series of 171 cases"],"prefix":"10.1038","volume":"29","author":[{"given":"Z.","family":"Mian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Gianduzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Kua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6566-9037","authenticated-orcid":false,"given":"J.","family":"Yaxley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"1148_CR1","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/bju.14951","volume":"125","author":"A Blazevski","year":"2020","unstructured":"Blazevski A, Scheltema MJ, Amin A, Thompson JE, Lawrentschuk N, Stricker PD. Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment. BJU Int. 2020;125:369\u201378.","journal-title":"BJU Int"},{"key":"1148_CR2","doi-asserted-by":"publisher","first-page":"94","DOI":"10.2967\/jnumed.123.266164","volume":"65","author":"L Emmett","year":"2024","unstructured":"Emmett L, Papa N, Counter W, Calais J, Barbato F, Burger, et al. Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database. J Nucl Med. 2024;65:94\u201399. https:\/\/doi.org\/10.2967\/jnumed.123.266164.","journal-title":"J Nucl Med"},{"key":"1148_CR3","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.21037\/tau-2025-678","volume":"14","author":"J Cheng","year":"2025","unstructured":"Cheng J, Adhami M, King D, Yaxley J, Kavnoudias H, Grummet J. Focal irreversible electroporation for the treatment of localised prostate cancer: a systematic review. Transl Androl Urol. 2025;14:4012\u201332. https:\/\/doi.org\/10.21037\/tau-2025-678.","journal-title":"Transl Androl Urol"},{"key":"1148_CR4","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.juro.2011.03.147","volume":"186","author":"Ahmed HU","year":"2011","unstructured":"Ahmed HU, Hu Y, Carter T, Arumainayagam N, Lecornet E, Freeman A, et al. Characterizing clinically significant pros tate cancer using template prostate mapping biopsy. J Urol. 2011;186:458\u201364.","journal-title":"J Urol"},{"key":"1148_CR5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/JU.0000000000003051","volume":"209","author":"J de la Rosette","year":"2023","unstructured":"de la Rosette J, Dominguez-Escrig J, Zhang K, Teoh J, Barret E, Ramon-Borja JC,8, et al. A Multicenter, Randomized, Single-blind, 2-Arm Intervention Study Evaluating the Adverse Events and Quality of Life After Irreversible Electroporation for the Ablation of Localized Low-intermediate Risk Prostate Cancer. J Urol. 2023;209:347\u201353. https:\/\/doi.org\/10.1097\/JU.0000000000003051.","journal-title":"J Urol"},{"key":"1148_CR6","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/JU.0000000000004253","volume":"213","author":"SV Carlsson","year":"2025","unstructured":"Carlsson SV, Carroll PR, Hamdy FC. Reevaluating the Definition of Clinically Significant Prostate Cancer as Grade Groups 2 to 5: An Imperative for Improved Risk Stratification. J Urol. 2025;213:238\u201341. https:\/\/doi.org\/10.1097\/JU.0000000000004253.","journal-title":"J Urol"},{"key":"1148_CR7","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41391-023-00783-y","volume":"27","author":"K Zhang","year":"2024","unstructured":"Zhang K, Stricker P, L\u00f6hr M, Stehling M, Suberville M, Cussenot O, et al. A multi-center international study to evaluate the safety, functional and oncological outcomes of irreversible electroporation for the ablation of prostate cancer. Prostate Cancer Prostatic Dis. 2024;27:525\u201330. https:\/\/doi.org\/10.1038\/s41391-023-00783-y.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1148_CR8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.eururo.2025.06.003","volume":"89","author":"AK George","year":"2026","unstructured":"George AK, Miocinovic R, Patel AR, Lomas DJ, Correa AF, Chen DYT, et al. Irreversible Electroporation for Prostate Tissue Ablation in Patients with Intermediate-risk Prostate Cancer: Results from the PRESERVE Trial. Eur Urol. 2026;89:57\u201368. https:\/\/doi.org\/10.1016\/j.eururo.2025.06.003.","journal-title":"Eur Urol"},{"key":"1148_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/bju.15883","volume":"131","author":"S Ong","year":"2023","unstructured":"Ong S, Chen K, Grummet J, Yaxley J, Scheltema MJ, Stricker P, et al. Guidelines of guidelines: Focal therapy for prostate cancer, is it time for consensus? BJU Int. 2023;131:20\u201331. https:\/\/doi.org\/10.1111\/bju.15883.","journal-title":"BJU Int"},{"key":"1148_CR10","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41391-020-00315-y","volume":"24","author":"TT Shah","year":"2021","unstructured":"Shah TT, Reddy D, Peters M, Ball D, Kim NH, Gomez EG, et al. Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study. Prostate Cancer Prostatic Dis. 2021;24:567\u201374. https:\/\/doi.org\/10.1038\/s41391-020-00315-y.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1148_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/bju.15946","volume":"131","author":"MJ Scheltema","year":"2023","unstructured":"Scheltema MJ, Geboers B, Blazevski A, Doan P, Katelaris A, Agrawal S, et al. Median 5-year outcomes of primary focal irreversible electroporation for localised prostate cancer. BJU Int. 2023;131:6\u201313. https:\/\/doi.org\/10.1111\/bju.15946.","journal-title":"BJU Int"},{"key":"1148_CR12","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","volume":"388","author":"FC Hamdy","year":"2023","unstructured":"Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Davis M, Turner EL, et al. ProtecT Study Group. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med. 2023;388:1547\u201358. https:\/\/doi.org\/10.1056\/NEJMoa2214122.","journal-title":"N Engl J Med"},{"key":"1148_CR13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.euros.2025.01.012","volume":"72","author":"R Leni","year":"2025","unstructured":"Leni R, Vertosick EA, Liso N, Akin O, Carlsson SV, Montorsi F, et al. Confirmatory Biopsy Outcomes in Patients with Grade Group 2 Prostate Cancer: Implications for Early Management. Eur Urol Open Sci. 2025;72:46\u201353. https:\/\/doi.org\/10.1016\/j.euros.2025.01.012.","journal-title":"Eur Urol Open Sci"},{"key":"1148_CR14","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1007\/s00345-018-2281-z","volume":"36","author":"MJ Scheltema","year":"2018","unstructured":"Scheltema MJ, Chang JI, B\u00f6hm M, van den Bos W, Blazevski A, Gielchinsky I, et al. Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomy. World J Urol. 2018;36:1383\u20139. https:\/\/doi.org\/10.1007\/s00345-018-2281-z.","journal-title":"World J Urol"},{"key":"1148_CR15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.euros.2023.03.003","volume":"51","author":"A Lantz","year":"2023","unstructured":"Lantz A, Nordlund P, Falagario U, J\u00e4derling F, \u00d6zbek O, Clements M, et al. Prostate Cancer IRE Study (PRIS): A Randomized Controlled Trial Comparing Focal Therapy to Radical Treatment in Localized Prostate Cancer. Eur Urol Open Sci. 2023;51:89\u201394. https:\/\/doi.org\/10.1016\/j.euros.2023.03.003.","journal-title":"Eur Urol Open Sci"},{"key":"1148_CR16","doi-asserted-by":"publisher","unstructured":"Hamdy FC, Elliott D, le Conte S, Davies LC, Burns RM, Thomson C, et al. Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT. Health Technol Assess. 2018;22:1\u201396. https:\/\/doi.org\/10.3310\/hta22520.","DOI":"10.3310\/hta22520"},{"key":"1148_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-022-00978-w","volume":"22","author":"A Blazevski","year":"2022","unstructured":"Blazevski A, Gondoputro W, Scheltema MJ, Amin A, Geboers B, Barreto D, et al. Salvage robot-assisted radical prostatectomy following focal ablation with irreversible electroporation: feasibility, oncological and functional outcomes. BMC Urol. 2022;22:28. https:\/\/doi.org\/10.1186\/s12894-022-00978-w.","journal-title":"BMC Urol"},{"key":"1148_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.eururo.2019.03.007","volume":"76","author":"L Marconi","year":"2019","unstructured":"Marconi L, Stonier T, Tourinho-Barbosa R, Moore C, Ahmed HU, Cathelineau X. ret al. Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence. Eur Urol. 2019;76:27\u201330. https:\/\/doi.org\/10.1016\/j.eururo.2019.03.007.","journal-title":"Eur Urol"},{"key":"1148_CR19","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/bju.16720","volume":"136","author":"K Zhang","year":"2025","unstructured":"Zhang K, Teoh J, Laguna P, Dominguez-Escrig J, Barret E, et al. The diagnostic value of MRI for persistent prostate cancer following irreversible electroporation focal therapy. BJU Int. 2025;136:120\u20137. https:\/\/doi.org\/10.1111\/bju.16720.","journal-title":"BJU Int"},{"key":"1148_CR20","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/j.euf.2022.04.010","volume":"8","author":"B Geboers","year":"2022","unstructured":"Geboers B, Gondoputro W, Thompson JE, Reesink DJ, van Riel L, Zhang D, et al. Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Irreversible Electroporation-A Multicenter Validation Study. Eur Urol Focus. 2022;8:1591\u20138. https:\/\/doi.org\/10.1016\/j.euf.2022.04.010.","journal-title":"Eur Urol Focus"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01148-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01148-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01148-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:03:40Z","timestamp":1793289820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01148-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1148"],"URL":"https:\/\/doi.org\/10.1038\/s41391-026-01148-x","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"9 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}